This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

PF05

Ensysce Biosciences, Inc.

Drug Names(s): PF-05

Description: PF05 acts as an antagonist on the peripherally located mu-opioid receptors.

Deal Structure: Ensysce and Signature
In December 2015, Ensysce Biosciences and Signature Therapeutics announced the completion of a formal merger. The company will retain the name of Ensysce Biosciences and will be relocating to San Diego, California. Ensysce becomes an integrated drug delivery company for both small and large molecules.


PF05 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug